Atleast seven people have died after they suffered blood clots due to the Oxford-AstraZeneca vaccine, reported AFP quoting the UK medical regulator. The UK had reported that 30 people had suffered blood clots after the jab.

This comes as several European countries have blocked the use of the AstraZeneca jab over a potential link to blood clots. Releasing a statement, UK’s Medicines and Healthcare products Regulatory Agency said, “Out of the 30 reports up to and including 24 March, sadly 7 have died.”

Also Read| Family files complaint after French woman dies post AstraZeneca shot

The Netherlands on Friday halted vaccinations with the AstraZeneca jab for people under the age of 60 after five new cases among women, one of whom died. Germany took a similar decision earlier this week.

The European Medicines Agency (EMA), which like the World Health Organization previously declared the AstraZeneca vaccine safe, is expected to announce updated advice on the issue on April 7.

Also Read| France to close schools, go into limited lockdown amid surging COVID cases

The EMA said again on Wednesday it believes the vaccine is safe and that experts have found no specific risk factors such as age, gender or medical history. The UK regulator said that the 30 reports of thrombosis, submitted by medics or members of the public via a government website, came after 18.1 million doses of the vaccine had been administered in the country.

Most of the cases (22) were cerebral venous sinus thrombosis, a rare condition when a blood clot forms in the brain. Eight other cases saw people suffer thrombosis and low levels of blood platelets, which help blood clot.

Also Read| EU regulator says AstraZeneca is safe, conducting further analysis

There were no reports of blood clots from the Pfizer/BioNTech vaccine it said, adding that “our thorough review into these reports is ongoing. “The regulator’s website says that on the basis of current data, the benefits of the vaccines against COVID-19 “continue to outweigh any risks”.

AstraZeneca said last month following US efficiency trials that its vaccine is 79 percent effective at preventing the disease and does not increase the risk of blood clots. The UK has administered more than 31 million first vaccine doses, using both the Oxford-AstraZeneca and the Pfizer-BioNTech jabs. People cannot choose which one they get.

The UK in June 2020 ordered 100 million doses of the Oxford-AstraZeneca vaccine and supported its development. It also ordered 30 million doses of the Pfizer-BioNTech vaccine the same year.